menu
    • menu
    [{"orgOrder":0,"company":"Alcon Research Ltd","sponsor":"OcuMension Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"HYDROXYPROPYLMETHYLCELLULOSE","moa":"||Undisclosed","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Alcon Research Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alcon Research Ltd \/ OcuMension Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Alcon Research Ltd \/ OcuMension Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Dextrans

    Menu

    Dextrans

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alcon Research Ltd

                            Country arrow
                            AGGSpend
                            Not Confirmed

                            Alcon Research Ltd

                            Country arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : OcuMension Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            OcuMension Acquires Alcon Eye Drops with 16.7% Equity, Strategic Partnership Begins

                            Details : OcuMension will acquire outright, Tears Natural Forte, Bion Tears, Alcaine, Fluorescite, and Cyclogyl, in the Chinese market and AR-15512, a novel topical drug candidate for dry eye.

                            Product Name : Tears Naturale Forte

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 08, 2024

                            Lead Product(s) : HYDROXYPROPYLMETHYLCELLULOSE,Dextrans,Glycerine

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : OcuMension Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth